Proceedings: A correlation between the response to debrisoquine and the amount of unchanged drug excreted in the urine.
作者信息
Angelo M, Dring L G, Lancaster R, Latham A, Smith R L
出版信息
Br J Pharmacol. 1975 Oct;55(2):264P.
Abstract
摘要
相似文献
1
2
Clinical trials with Tendor (debrisoquine sulfate).
Ther Hung. 1974;22(4):165-71.
3
[On the hypotensive effect of debrisoquin sulfate (Declinax)].[关于硫酸地昔帕明（Declinax）的降压作用]
Rev Med Univ Navarra. 1973 Dec;17(4):339-44.
4
A longitudinal study of the mechanisms of action of debrisoquine and propranolol.关于异喹胍和普萘洛尔作用机制的纵向研究。
Br J Clin Pharmacol. 1978 Jul;6(1):43-50. doi: 10.1111/j.1365-2125.1978.tb01680.x.
5
Why hypertensive patients vary in their response to oral debrisoquine.为何高血压患者对口服异喹胍的反应存在差异。
Br Med J. 1977 Feb 12;1(6058):422-5. doi: 10.1136/bmj.1.6058.422.
6
Hypotensive response to debrisoquine and hydroxylation phenotype.
Life Sci. 1978 Mar;22(11):979-83. doi: 10.1016/0024-3205(78)90363-6.
7
Interaction between debrisoquine and phenylephrine in man.人体内异喹胍与去氧肾上腺素之间的相互作用。
Br J Pharmacol. 1973 Mar;47(3):675P-676P.
8
Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man.
Drug Metab Dispos. 1975 Sep-Oct;3(5):332-7.
9
A study of the debrisoquine hydroxylation polymorphism in a Nigerian population.尼日利亚人群中异喹胍羟基化多态性的研究。
Xenobiotica. 1980 Nov;10(11):811-8. doi: 10.3109/00498258009033811.
10
Proceedings: Parasympathetic blockade in patients treated with debrisoquine and with propranolol.论文集：用异喹胍和普萘洛尔治疗的患者中的副交感神经阻滞
West Afr J Pharmacol Drug Res. 1974 Dec;2(1):53P-54P.
引用本文的文献
1
Importance of Publishing Adverse Drug Reaction Case Reports: Promoting Public Health and Advancing Pharmacology and Therapeutics.发表药品不良反应病例报告的重要性：促进公众健康并推动药理学与治疗学发展
Drug Saf Case Rep. 2017 Sep 20;4(1):11. doi: 10.1007/s40800-017-0053-0.
2
Personalized medicine - where do we stand? Pouring some water into wine: a realistic perspective.个性化医疗——我们现状如何？往酒里掺水：一个现实的视角。
Croat Med J. 2012 Aug;53(4):314-20. doi: 10.3325/cmj.2012.53.314.
3
3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.3,4-脱氢去甲丙咪嗪，一种由4-羟基去甲丙咪嗪形成的新型去甲丙咪嗪代谢物，它会影响CYP2D6代谢率。
Drug Metab Dispos. 2006 Sep;34(9):1563-74. doi: 10.1124/dmd.105.008920. Epub 2006 Jun 16.
4
Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.多态性药物氧化：药代动力学基础及实验指标比较
Br J Clin Pharmacol. 1986 Nov;22(5):541-50. doi: 10.1111/j.1365-2125.1986.tb02933.x.
5
The metabolism of [14C]-debrisoquine in man.人体中[14C]-异喹胍的代谢
Br J Clin Pharmacol. 1979 Mar;7(3):257-66. doi: 10.1111/j.1365-2125.1979.tb00930.x.
本文引用的文献
1
Quantitative determination of guanethidine and other guanido-containing drugs in biological fluids by gas chromatography with flame ionization detection and multiple ion detection.
Anal Chem. 1974 Jan;46(1):34-9. doi: 10.1021/ac60337a045.
Zotero 插件